Warning Letter Wednesday® Posts
A weekly exploration of FDA warning letters and enforcement trends
Takeaway -
Even lower risk statements can trigger NAD scrutiny
Takeaway -
Copackers & distributors must comply with GMPs
Takeaway -
Flu & virus claims are enough for regulatory action
Takeaway -
Specifications continue to be cited
Takeaway -
Unsafe products marketed to children are deceptive
Takeaway -
Food safety plans should be comprehensive
Takeaway -
Review of NAD case
Takeaway -
Blogs can be considered marketing
Takeaway -
Email newsletters are marketing
Takeaway -
Reduce litigation by following labeling rules
Takeaway -
Sponsored children’s content has increased disclosure requirements
Takeaway -
Study design must be correct